

Patent Docket No. P1834

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

In re Application of

Ellen H. Filvaroff

Serial No.: 09/685,823

Filed: October 9, 2000

Washington, DC 20231

For: Use of IL-17 and LIF Antagonists for the

Commissioner of Patents and Trademarks

Treatment of Cartilagenous Disorders

Group Art Unit: 1646

Examiner: D. Jiang

Technology Center 2600

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Box Sequence, Commissioner of Patents and Trademarks, Washington, DC 20231 on

pril 4, 2001

Glory L. Tabuena

RESPONSE TO RESTRICTION

Technology Center 2600

Sir:

In response to Examiner Jiang's Restriction dated March 26, 2001, Applicant hereby elects, without traverse, Group 1, drawn to a method of treating or preventing cartilage damage with an antagonist to IL-17. With respect to the species election further defining the cartilage agent, Applicant hereby elects the IL-1 receptor antagonist (IL-1ra) species of the subgenus "catabolism antagonist" detailed as a Markush group in Claim 18.

The Commissioner is authorized to charge any additional fees due in connection with the filing of this document to our Deposit Account No. 07-0630. A duplicate copy of this transmittal is enclosed.

Respectfully submitted,

GENENTECH, INC.

Date: April 4, 2001

Craig G. Svoboda

Reg. No. 39,044

Telephone: (650) 225-1489

09157

PATENT TRADEMARK OFFICE